Soon-to-merge French biotechs OSE Pharma (Euronext Paris :OSE) and Effimune have launched a hepatocellular carcinoma (primary liver cancer) study under a private-public collaborative program.
The MDScan (Myeloid-Derived Suppressor Cells Analysis) research program is supported by the French National Cancer Institute along with national government and further academic and research bodies, having been selected for backing following a competitive process.
Entitled Control of suppressive myeloid cells by SIRP-alpha: investigation in hepatocellular carcinoma, the study aims to measure the SIRP-alpha marker (Signal Regulatory Protein α) in liver cancer patients. It will evaluate the activity of Effi-DEM, the new checkpoint inhibitor targeting suppressor myeloid and macrophage cells.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze